Tilmann Roos | Senior Director Early Process Development
CureVac AG

Tilmann Roos, Senior Director Early Process Development, CureVac AG

Dr. Tilmann Roos has over 14 years’ experience in biotechnical product and process development. He has worked as assistant professor for medicinal microbiology and biotechnology at the University of Stuttgart/Hohenheim and at the Applied University Esslingen. Furthermore, he was assessor at the Federal German Health Authority, Paul-Ehrlich Institute, as an expert for CMC and preclinical studies. He has comprehensive interdisciplinary expertise.

Dr. Roos, as Senior Director of Early Process Development, is responsible for the development of alternative purification strategies, process automation, product characterization and analytical method development at CureVac AG.


Day 2, April 8 @ 09:40

Interactive panel: Unique rapid production opportunities and challenges that face RNA delivery and manufacture

  • Why and where will it make a difference?
  • How is it difference to DNA vaccines?
  • What are the unique challenges and advantages of RNA vaccine?
  • How will RNA vaccines help in an outbreak like corona? Can the scale-up/volume be big enough?
  • Advantages of RNA are clearly from the speed and applicability to ID and cancer, but does the speed have any affect on the overall quality of the vaccine?
last published: 05/Mar/20 10:35 GMT

back to speakers

Sign Up for Event Updates